ACE and Tako-tsubo cardiomyopathy: Coupled with registry data which point to a significant survival benefit of this class of drugs,2 it follows that angiotensin‐converting enzyme inhibition may have therapeutic potential and would be prime candidate for randomized controlled trials of improving the long‐term outcomes for patients with takotsubo cardiomyopathy.